UNITEX
12.1.2022 09:32:08 CET | Business Wire | Press release
UNITEX Corporation (Representative: Emi Kosugi, President / Office: Machida, Tokyo), the leader in the computer storage space for over 30 years, is pleased to announce today that its popular USB LTO tape drive will be available with LTO-9 technology in the spring of 2022. It features USB connectivity, a native storage capacity of 18TB and compressed storage capacity at 2.5:1 of 45TB, and a data transfer rate of up to 300MB/second.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220111005635/en/
UNITEX USB LTO-9 highlights
-
LTO-9 tape archiving solution with the world’s only USB connectivity
You can use USB LTO-9 by connecting to laptop PCs and other USB devices to store large volumes of data anywhere, conveniently, with small IT-invested. Both half-height (HH) and full-height (FH) drives are available.
-
Increased capacity. Increased speed.
Offering up to 45TB of storage capacity (18TB for non-compressed data), a 50% greater capacity than LTO-8. Transfer speeds with USB connection reach up to 300MB/ second, a 25% faster than the previous USB LTO-8.
-
Offering protection against cybercrime
LTO tape can be stored offline and off-network, creating a physical “air gap” of protection to minimize the risk of data exposure to cyberattacks. In addition UNITEX archiving software protects your data safely with tamper-proof by hash value and encryption functions.
-
Lower environmental impact
LTO tape and USB connectivity have a significantly lower environmental impact as there is no need to have it constantly powered-on during data storage, thereby reducing CO2 emissions generated by 94% (*1) when compared to hard disk drives (HDDs). *1 Source: JEITA tape storage committee
About UNITEX Corporation
UNITEX Corporation has specialized in the computer storage space since it was founded in 1990. Over the years, UNITEX has developed various driver and application software, greatly increasing interoperability and making storage devices compatible across the entire spectrum of computer operating systems. This solid history and experiences make UNITEX an extremely reliable data storage solution provider.
Main product categories
- The world's only USB LTO data storage system
- Financial system solutions for high-security data conversion and migration
- Multi-optical disk systems with high-performance robot arms
Company Name: UNITEX Corporation
Representative: Emi Kosugi, President
Headquarter: 2-2-4 Nakamachi, Machida, Tokyo, Japan
Establishment: October, 1990
Capital: US$800,000
URL: https://www.unitex.co.jp/en
View source version on businesswire.com: https://www.businesswire.com/news/home/20220111005635/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom